Barclays lowered the firm’s price target on Patterson-UTI (PTEN) to $7 from $8 and keeps an Overweight rating on the shares post the Q2 report. The company’s Q3 outlook reflects the softening activity and pricing environment in North America, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTEN:
- Patterson-UTI price target lowered to $10 from $12 at Stifel
- Patterson-UTI price target lowered to $8.50 from $9 at RBC Capital
- Patterson-UTI Energy Reports Q2 2025 Financial Results
- Patterson-UTI Energy Navigates Challenges with Optimism
- Patterson-UTI: Strong Financial Performance and Promising Outlook Support Buy Rating